golimumab vs infliximab-dyyb (Zymfentra)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
golimumab · Simponi
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
infliximab-dyyb (Zymfentra)
Marketed by Celltrion
NCT03945019 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 396 participants entering induction and 343 entering the randomized maintenance comparison (231 receiving CT-P13 SC and 112 placebo). Both prespecified primary endpoints—CDAI-based clinical remission and endoscopic response at week 54—were met, with each comparison reported as p<0.0001.
Next expected readout: December 2026 · NCT06064864 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | golimumab | infliximab-dyyb (Zymfentra) |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Not reported |
| Endoscopic response (induction) | —Not reported | —Not reported |
| Clinical remission (maintenance) | —Not reported | —Not reported |
| Endoscopic response (maintenance) | —Not reported | —Not reported |
Clinical remission (induction)
- golimumab
- —Not reported
- infliximab-dyyb (Zymfentra)
- —Not reported
Endoscopic response (induction)
- golimumab
- —Not reported
- infliximab-dyyb (Zymfentra)
- —Not reported
Clinical remission (maintenance)
- golimumab
- —Not reported
- infliximab-dyyb (Zymfentra)
- —Not reported
Endoscopic response (maintenance)
- golimumab
- —Not reported
- infliximab-dyyb (Zymfentra)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
golimumab: registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.
infliximab-dyyb (Zymfentra): registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
golimumab · Simponi
Marketed by Johnson & Johnson
NCT01863771 · Phase 3 · completed
Design meets the 'strong' bar: randomized, double-blind (participant and investigator masked), placebo-controlled, phase 3, with a hard clinical endpoint (Mayo score-based clinical response); the primary comparison was clearly met in the favorable direction (18/32 vs 6/31, non-overlapping 95% CIs).
Reported efficacy
Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4) (met)
Result source: NCT01863771
infliximab-dyyb (Zymfentra)
Marketed by Celltrion
NCT04205643 · Phase 3 · completed
The trial was randomized, quadruple-blind, and placebo-controlled, with 548 participants enrolled and 438 participants included in the reported maintenance analysis. The hard clinical primary endpoint—clinical remission by the modified Mayo score at week 54—was met, with 127 of 294 participants receiving CT-P13 versus 30 of 144 receiving placebo (p<0.0001).
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | golimumab | infliximab-dyyb (Zymfentra) |
|---|---|---|
| Clinical remission (induction) | 17.9% vs 6.4%+11.5 vs placeboNCT004875391 other result
| —Not reported |
| Clinical remission (maintenance) | —Trial running · NCT03596645 | —Not reported |
| Clinical response (induction) | 54.9% vs 30.3%+24.6 vs placeboNCT004875391 other result
| —Not reported |
| Endoscopic improvement (induction) | —Trial running · NCT03596645 | —Not reported |
| Corticosteroid-free remission (maintenance) | 23.2% vs 18.4%+4.8 vs placeboNCT004886311 other result
| —Not reported |
Clinical remission (induction)
- golimumab
- 17.9% vs 6.4%+11.5 vs placeboNCT00487539
1 other result
- 17.8% vs 6.4% NCT00487539
- infliximab-dyyb (Zymfentra)
- —Not reported
Clinical remission (maintenance)
- golimumab
- —Trial running · NCT03596645
- infliximab-dyyb (Zymfentra)
- —Not reported
Clinical response (induction)
- golimumab
- 54.9% vs 30.3%+24.6 vs placeboNCT00487539
1 other result
- 51% vs 30.3% NCT00487539
- infliximab-dyyb (Zymfentra)
- —Not reported
Endoscopic improvement (induction)
- golimumab
- —Trial running · NCT03596645
- infliximab-dyyb (Zymfentra)
- —Not reported
Corticosteroid-free remission (maintenance)
- golimumab
- 23.2% vs 18.4%+4.8 vs placeboNCT00488631
1 other result
- 28.2% vs 18.4% NCT00488631
- infliximab-dyyb (Zymfentra)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
infliximab-dyyb (Zymfentra): registry results are on file for Ulcerative Colitis, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. golimumab: 4 of 4 rows · infliximab-dyyb (Zymfentra): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | golimumab |
|---|---|
| Dropout rate | —100 mga NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 28 more results—100 mg NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 14.6%Group1: Golimumab [Induction] NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —200 mg NCT00488631 · Phase 3 29.2%100 mg NCT00488631 · Phase 3 · combination —100 mg - 200 mg NCT00488631 · Phase 3 53.3%100 mg NCT00488631 · Phase 3 · monotherapy —100 mg - 200 mg NCT00488631 · Phase 3 —100 mg NCT00488631 · Phase 3 44.8%100 mg NCT00488631 · Phase 3 · monotherapy —100 mg NCT00488631 · Phase 3 27.9%50 mg NCT00488631 · Phase 3 · combination —50 mg - 100 mg NCT00488631 · Phase 3 —50 mg - 100 mg NCT00488631 · Phase 3 —50 mg NCT00488631 · Phase 3 —50 mg NCT00488631 · Phase 3 1.2%400 mg -> 200 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 0.9%200 mg -> 100 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 4.2%100 mg -> 50 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 7.1%Golimumab Induction Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 4.3%Golimumab Maintenance Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 23.7% NCT02318667 · Phase 4 · registry result, not featured evidence 17.1% NCT02092285 · Phase 4 · registry result, not featured evidence 0%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 6.9%Combination Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Monotherapy Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Safety Follow-up: Golimumab Monoth NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Discontinued due to AEs | —100 mga NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 28 more results—100 mg NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 6.3%Group1: Golimumab [Induction] NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —200 mg NCT00488631 · Phase 3 7.8%100 mg NCT00488631 · Phase 3 · combination —100 mg - 200 mg NCT00488631 · Phase 3 12.3%100 mg NCT00488631 · Phase 3 · monotherapy —100 mg - 200 mg NCT00488631 · Phase 3 —100 mg NCT00488631 · Phase 3 13%100 mg NCT00488631 · Phase 3 · monotherapy —100 mg NCT00488631 · Phase 3 7.8%50 mg NCT00488631 · Phase 3 · combination —50 mg - 100 mg NCT00488631 · Phase 3 —50 mg - 100 mg NCT00488631 · Phase 3 —50 mg NCT00488631 · Phase 3 —50 mg NCT00488631 · Phase 3 0.3%400 mg -> 200 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 0.3%200 mg -> 100 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 2.8%100 mg -> 50 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 —Golimumab Induction Therapy NCT03124121 · Phase 4 · registry result, not featured evidence —Golimumab Maintenance Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 2.6% NCT02318667 · Phase 4 · registry result, not featured evidence 3.4% NCT02092285 · Phase 4 · registry result, not featured evidence 0%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 0%Combination Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Monotherapy Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Safety Follow-up: Golimumab Monoth NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Serious AEs | 3.1%100 mga NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 28 more results10%100 mg NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 3.5%Group1: Golimumab [Induction] NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 14.3%200 mg NCT00488631 · Phase 3 14.3%100 mg NCT00488631 · Phase 3 · combination 7.1%100 mg - 200 mg NCT00488631 · Phase 3 15.6%100 mg NCT00488631 · Phase 3 · monotherapy 0%100 mg - 200 mg NCT00488631 · Phase 3 19.4%100 mg NCT00488631 · Phase 3 14.8%100 mg NCT00488631 · Phase 3 · monotherapy 25%100 mg NCT00488631 · Phase 3 8.4%50 mg NCT00488631 · Phase 3 · combination 24%50 mg - 100 mg NCT00488631 · Phase 3 5.3%50 mg - 100 mg NCT00488631 · Phase 3 11.8%50 mg NCT00488631 · Phase 3 0%50 mg NCT00488631 · Phase 3 4.5%400 mg -> 200 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 3%200 mg -> 100 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 4.2%100 mg -> 50 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 9.5%Golimumab Induction Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 0%Golimumab Maintenance Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 10.5% NCT02318667 · Phase 4 · registry result, not featured evidence 23.9% NCT02092285 · Phase 4 · registry result, not featured evidence 1.4%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Combination Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy 4.2%Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 4.5%Monotherapy Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy 0%Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination 0%Safety Follow-up: Golimumab Monoth NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Most frequent reported AEs | 100 mga nasopharyngitis 53.1% (placebo 22.6%) injection site erythema 15.6% (placebo 0%) influenza 12.5% (placebo 3.2%) NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 26 more results100 mg nasopharyngitis 23.3% (placebo 22.6%) colitis ulcerative 6.7% (placebo 6.5%) upper respiratory tract inflammation 6.7% (placebo 0%) NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 nasopharyngitis 11.8% (placebo 22.6%) colitis ulcerative 4.9% (placebo 6.5%) injection site erythema 3.5% (placebo 0%) NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 200 mg colitis ulcerative 28.6% (placebo 18.6%) gastroenteritis viral 28.6% (placebo 0%) nasopharyngitis 28.6% (placebo 6.4%) NCT00488631 · Phase 3 100 mg nasopharyngitis 14.9% (placebo 6.4%) colitis ulcerative 11.7% (placebo 18.6%) headache 7.8% (placebo 9%) NCT00488631 · Phase 3 · combination 100 mg - 200 mg nasopharyngitis 21.4% (placebo 6.4%) headache 14.3% (placebo 9%) viral upper respiratory tract infection 14.3% (placebo 0%) NCT00488631 · Phase 3 100 mg colitis ulcerative 12.1% (placebo 18.6%) nasopharyngitis 8.1% (placebo 6.4%) arthralgia 7.2% (placebo 7.1%) NCT00488631 · Phase 3 · monotherapy 100 mg - 200 mg colitis ulcerative 30% (placebo 18.6%) diarrhoea 20% (placebo 4.5%) gastroenteritis 20% (placebo 1.9%) NCT00488631 · Phase 3 100 mg colitis ulcerative 23.7% (placebo 18.6%) nasopharyngitis 16.4% (placebo 6.4%) sinusitis 9% (placebo 1.9%) NCT00488631 · Phase 3 100 mg colitis ulcerative 10.9% (placebo 18.6%) headache 9.6% (placebo 9%) nasopharyngitis 7.4% (placebo 6.4%) NCT00488631 · Phase 3 · monotherapy 100 mg colitis ulcerative 25% (placebo 18.6%) nasopharyngitis 14.3% (placebo 6.4%) arthralgia 10.7% (placebo 7.1%) NCT00488631 · Phase 3 50 mg colitis ulcerative 16.2% (placebo 18.6%) nasopharyngitis 9.1% (placebo 6.4%) headache 8.4% (placebo 9%) NCT00488631 · Phase 3 · combination 50 mg - 100 mg nasopharyngitis 16% (placebo 6.4%) pyrexia 16% (placebo 4.5%) upper respiratory tract infection 12% (placebo 2.6%) NCT00488631 · Phase 3 50 mg - 100 mg colitis ulcerative 10.5% (placebo 18.6%) dyspepsia 10.5% (placebo 1.3%) upper respiratory tract infection 10.5% (placebo 2.6%) NCT00488631 · Phase 3 50 mg colitis ulcerative 18.3% (placebo 18.6%) nasopharyngitis 10.8% (placebo 6.4%) arthralgia 9.7% (placebo 7.1%) NCT00488631 · Phase 3 50 mg abdominal pain 100% (placebo 2.6%) abdominal pain upper 100% (placebo 0.6%) bite 100% (placebo 0%) NCT00488631 · Phase 3 400 mg -> 200 mg headache 4.5% (placebo 5.2%) nausea 3.6% (placebo 1.8%) pyrexia 3% (placebo 2.1%) NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 200 mg -> 100 mg nasopharyngitis 3.9% (placebo 3.6%) headache 3.3% (placebo 5.2%) anaemia 2.4% (placebo 1.8%) NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 100 mg -> 50 mg headache 7% (placebo 5.2%) injection site erythema 4.2% (placebo 0%) anaemia 2.8% (placebo 1.8%) NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 colitis ulcerative 10.5% NCT02318667 · Phase 4 · registry result, not featured evidence colitis ulcerative 13.7% nasopharyngitis 9.8% colitis 7.3% NCT02092285 · Phase 4 · registry result, not featured evidence anaemia 5.6% colitis ulcerative 5.6% headache 5.6% NCT03662542 · Phase 2 · registry result, not featured evidence · combination colitis ulcerative 11.1% anaemia 6.9% upper respiratory tract infection 5.6% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy colitis ulcerative 8.5% upper respiratory tract infection 8.5% headache 4.2% NCT03662542 · Phase 2 · registry result, not featured evidence · combination colitis ulcerative 7.5% anaemia 3% headache 3% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy anaemia 0% colitis ulcerative 0% headache 0% NCT03662542 · Phase 2 · registry result, not featured evidence · combination colitis ulcerative 5.2% anaemia 0% headache 0% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
Notes
- aPopulation comparability has not been reviewed for 23 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
golimumab
show 4 more results
show 2 more results
show 2 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: golimumab's landscape · infliximab-dyyb (Zymfentra)'s landscape